直接口服抗凝药物在肝硬化并发门静脉血栓中的治疗进展

王世美; 伍丽萍; 胡玲

doi:10.3969/j.issn.1001-5256.2023.01.031

直接口服抗凝药物在肝硬化并发门静脉血栓中的治疗进展

DOI: 10.3969/j.issn.1001-5256.2023.01.031

成都市第三人民医院，西南交通大学附属医院消化内科，成都 610031

基金项目:

成都市科技项目 (2021-YF05-00585-SN);

成都市卫健委科研项目 (2022484)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：王世美负责拟定写作思路，查阅文献，撰写论文；伍丽萍提供部分论文修改意见；胡玲校正文字及参考文献格式。

详细信息

通信作者:
王世美, wangshimei712@163.com (ORCID: 0000-0002-1222-7259)

计量
- 文章访问数: 1821
- HTML全文浏览量: 1268
- PDF下载量: 146
- 被引次数: 0
出版历程
- 收稿日期: 2022-05-07
- 录用日期: 2022-06-30
- 出版日期: 2023-01-20

Advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis

Department of Gastroenterology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu 610031, China

Research funding:

Science and Technology Project of Chengdu (2021-YF05-00585-SN);

Seientific Research Project of Chengdu's Municipal Health Commission (2022484)

More Information

Corresponding author: WANG Shimei, wangshimei712@163.com (ORCID: 0000-0002-1222-7259)

摘要

摘要: 门静脉血栓是肝硬化常见的并发症之一，目前主要的治疗方式是抗凝，因低分子肝素、维生素K拮抗剂为针剂或需监测国际标准化比值，而直接口服抗凝药物具有口服方便、无需监测国际标准化比值、血栓再通率高的优点，故后者成为了替代治疗的研究热点。本文通过总结直接口服抗凝药物在肝硬化并发门静脉血栓中的治疗进展，为进一步临床研究奠定基础。
- 肝硬化 /
- 抗凝药 /
- 利伐沙班
Abstract: Portal vein thrombosis is one of the common complications of liver cirrhosis, and anticoagulation is currently the main treatment method for this disease. Since low-molecular-weight heparin must be injected and vitamin K antagonists require regular monitoring of international normalized ratio (INR), direct oral anticoagulants have become a research hotspot in replacement therapy with the advantages of convenient oral administration, no need for INR monitoring, and high recanalization rate. This article summarizes the advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis, in order to lay a foundation for further clinical studies.
- Liver Cirrhosis /
- Anticoagulants /
- Rivaroxaban

HTML全文

参考文献(32)

[1]	KOH JH, LIEW ZH, NG GK, et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis[J]. Dig Liver Dis, 2022, 54(1): 56-62. DOI: 10.1016/j.dld.2021.07.039.
[2]	Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. J Dig Dis, 2021, 22(4): 176-186. DOI: 10.1111/1751-2980.12970.
[3]	PRIYANKA P, KUPEC JT, KRAFFT M, et al. Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis[J]. Int J Hepatol, 2018, 2018: 8432781. DOI: 10.1155/2018/8432781.
[4]	NORONHA FERREIRA C, REIS D, CORTEZ-PINTO H, et al. Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis[J]. Dig Dis Sci, 2019, 64(9): 2671-2683. DOI: 10.1007/s10620-019-05572-z.
[5]	NAYMAGON L, TREMBLAY D, ZUBIZARRETA N, et al. Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis[J]. Dig Dis Sci, 2021, 66(10): 3619-3629. DOI: 10.1007/s10620-020-06695-4.
[6]	WANG L, GUO X, XU X, et al. Anticoagulation favors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: Results of a meta-analysis[J]. Adv Ther, 2021, 38(1): 495-520. DOI: 10.1007/s12325-020-01550-4.
[7]	DONG S, QI H, LI Y, et al. A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat?[J]. Hepatol Int, 2021, 15(6): 1356-1375. DOI: 10.1007/s12072-021-10233-3.
[8]	PETTINARI I, VUKOTIC R, STEFANESCU H, et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis[J]. Am J Gastroenterol, 2019, 114(2): 258-266. DOI: 10.1038/s41395-018-0421-0.
[9]	GHAZALEH S, BERAN A, ABURAYYAN K, et al. Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis: a systematic review and meta-analysis[J]. Ann Gastroenterol, 2021, 34(1): 104-110. DOI: 10.20524/aog.2020.0544.
[10]	GAO Y, LIU H, TANG F, et al. Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(2): 101649. DOI: 10.1016/j.clinre.2021.101649.
[11]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis[J]. J Hepatol, 2022, 76(5): 1151-1184. DOI: 10.1016/j.jhep.2021.09.003.
[12]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[13]	O'LEARY JG, GREENBERG CS, PATTON HM, et al. AGA Clinical Practice Update: coagulation in cirrhosis[J]. Gastroenterology, 2019, 157(1): 34-43. e1. DOI: 10.1053/j.gastro.2019.03.070.
[14]	NORTHUP PG, GARCIA-PAGAN JC, GARCIA-TSAO G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 73(1): 366-413. DOI: 10.1002/hep.31646.
[15]	ELHOSSEINY S, AL MOUSSAWI H, CHALHOUB JM, et al. Direct oral anticoagulants in cirrhotic patients: Current evidence and clinical observations[J]. Can J Gastroenterol Hepatol, 2019, 2019: 4383269. DOI: 10.1155/2019/4383269.
[16]	DOUROS A, AZOULAY L, YIN H, et al. Non-Vitamin K antagonist oral anticoagulants and risk of serious liver injury[J]. J Am Coll Cardiol, 2018, 71(10): 1105-1113. DOI: 10.1016/j.jacc.2018.01.009.
[17]	LV Y, BAI W, LI K, et al. Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: A prospective observational study[J]. Am J Gastroenterol, 2021, 116(7): 1447-1464. DOI: 10.14309/ajg.0000000000001194.
[18]	YAO W, FENG Y, LIU T, et al. Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: A randomized clinical trial[J]. EXCLI J, 2021, 20: 537-549. DOI: 10.17179/excli2020-3120.
[19]	NAGAOKI Y, AIKATA H, DAIJYO K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis[J]. Hepatol Res, 2018, 48(1): 51-58. DOI: 10.1111/hepr.12895.
[20]	MORT JF, DAVIS J, MAHORO G, et al. Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis[J]. Clin Gastroenterol Hepatol, 2021, 19(7): 1436-1442. DOI: 10.1016/j.cgh.2020.08.007.
[21]	SEMMLER G, POMEJ K, BAUER D, et al. Safety of direct oral anticoagulants in patients with advanced liver disease[J]. Liver Int, 2021, 41(9): 2159-2170. DOI: 10.1111/liv.14992.
[22]	AI MH, DONG WG, TAN XP, et al. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis[J]. Eur J Gastroenterol Hepatol, 2020, 32(10): 1395-1400. DOI: 10.1097/MEG.0000000000001846.
[23]	COSTACHE RS, DRAGOMIRICǍ AS, DUMITRAŞ EA, et al. Portal vein thrombosis: A concise review (Review)[J]. Exp Ther Med, 2021, 22(1): 759. DOI: 10.3892/etm.2021.10191.
[24]	CHUN HS, CHOE AR, LEE M, et al. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis[J]. Clin Mol Hepatol, 2021, 27(4): 535-552. DOI: 10.3350/cmh.2021.0109.
[25]	NG CH, TAN D, NISTALA K, et al. A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis[J]. Hepatol Int, 2021, 15(5): 1196-1206. DOI: 10.1007/s12072-021-10247-x.
[26]	MOHAN BP, ARAVAMUDAN VM, KHAN SR, et al. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis[J]. Ann Gastroenterol, 2020, 33(5): 521-527. DOI: 10.20524/aog.2020.0503.
[27]	DAVIS KA, JOSEPH J, NISLY SA. Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes[J]. J Thromb Thrombolysis, 2020, 50(2): 457-461. DOI: 10.1007/s11239-019-02035-0.
[28]	CHEN H, LEI J, LIANG S, et al. Safety and efficacy of anticoagulation in patients with cirrhosis: A Meta-Analysis[J]. Can J Gastroenterol Hepatol, 2021, 2021: 8859602. DOI: 10.1155/2021/8859602.
[29]	HANAFY AS, ABD-ELSALAM S, DAWOUD MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis[J]. Vascul Pharmacol, 2019, 113: 86-91. DOI: 10.1016/j.vph.2018.05.002.
[30]	WILLIAMS C, STEWART E, CONZEN KD, et al. Dabigatran reversal with idarucizumab in 2 patients with portal vein thrombosis undergoing orthotopic liver transplantation[J]. Semin Cardiothorac Vasc Anesth, 2021, 25(3): 200-207. DOI: 10.1177/1089253220982183.
[31]	DIBIASI C, WIEGELE M, GRATZ J. Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis[J]. J Clin Anesth, 2019, 56: 41-42. DOI: 10.1016/j.jclinane.2019.01.020.
[32]	HUANG ZC, LI CQ, LIU XY, et al. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review[J]. Cardiovasc Drugs Ther, 2021, 35(6): 1205-1215. DOI: 10.1007/s10557-020-07065-y.